From September 21 to 24, in order to implement the consensus reached by the leaders of China and Britain and strengthen Sino-British drug regulatory exchanges and cooperation, China Drug Administration Director Huang Guo was invited to lead a working visit to the UK. During the visit, Huang Guo held talks with Anthony Herndon, Chairman of the Board of the UK Medicines and Health Products Administration, and Lawrence Taran, and exchanged views on topics such as drug clinical trials, drug testing, pharmacovigilance, and AI medical device supervision, and reached a consensus on further deepening future cooperation. The two sides agreed that drug regulatory agencies of the two countries should work together to promote the development of the pharmaceutical industry and jointly address disease challenges. After the meeting, the National Drug Administration and the UK Medicines and Health Products Administration signed a letter of intent to cooperate, agreeing to gradually raise the level of mutual trust through continuous improvement of mutual understanding.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.